Finally, to assess the potential clinical relevance of HNRNPD, we assessed whether its knockout could sensitize HeLa cells to treatment with CPT, the precursor of a broad class of antineoplastic drugs widely used for the treatment of several tumours (55). The gene discussed is HNRNPD; the disease is neoplasm.